Gene-Disorder Association · Article
Gene
KRASKRAS Proto-Oncogene, GTPase
×
First reported
2009
Supporting publications
3
Manually curatedApproved treatment annotated
Association Review
In brief
The association between KRAS (KRAS Proto-Oncogene, GTPase) and Melanoma is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
2
Compounds
12
Trials
839of 10,093 via KRAS compounds
Publications
3
01
At a glance
Association overview
A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources
1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
2 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access
7 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
Mechanism overlap
Shared mechanisms
1 shared pathway
Biological pathways and phenotype concepts shared by the gene and the disorder, with supporting publications.
Request access
06
Interventions
Therapeutics
12 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
07
Human studies
Clinical trials
10,093 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
3 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access
09
Provenance
References & sources
13 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access